Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,122 total articles
John S. Vieceli, Chief Product Officer at Quantum-Si Inc (NASDAQ:QSI), executed two mandatory stock sales totaling $28,052 in late June 2026 to cover withholding taxes on vesting restricted stock units. The transactions occurred amid a period of significant stock volatility, with shares trading near $0.83. Despite recent operational milestones, inc…
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (NASDAQ:APGE), executed a sale of 26,400 shares on June 22, 2026, generating approximately $3.5 million. The transaction, governed by a pre-established Rule 10b5-1 plan adopted in September 2025, occurred as Apogee's stock approached a 52-week high of $133.16. This activity unfolds…
Evommune, Inc. (NASDAQ:EVMN) Chief Scientific Officer Jeegar Pravinkumar Patel executed a transaction involving the sale of 1,488 shares of company common stock on June 22, 2026, totaling $33,480. The sale was conducted under a Rule 10b5-1 trading plan adopted earlier in the year, coinciding with the exercise of 1,488 employee stock options at $3.8…
Quantum-Si Inc. (NASDAQ: QSI) Chief Executive Officer Jeffrey Alan Hawkins completed two stock sales in late June 2026, generating approximately $20,996 to cover mandatory tax withholdings associated with restricted stock unit vesting. The transactions occurred as the company reported better-than-expected first-quarter results and announced a new c…
MARA Holdings, Inc. (NASDAQ:MARA) director Douglas K. Mellinger executed a stock sale on June 22, 2026, selling 7,000 shares at $16.00 per share, totaling $112,000. The transaction was carried out under a Rule 10b5-1 trading plan established on March 6, 2025. Following the sale, Mellinger directly holds 231,618 shares and indirectly holds 15,000 sh…
Capricor Therapeutics, Inc. (NASDAQ: CAPR) reported the execution of a pre-arranged trading plan by its Chief Financial Officer, Anthony Bergmann. The sale of 900 shares was facilitated by options exercised from a long-term vesting schedule, following the adoption of the 10b5-1 plan in late 2025. This activity occurs against a backdrop of recent fi…
Michael Henderson, Chief Executive Officer of Apogee Therapeutics, Inc. (NASDAQ: APGE), executed a sale of 80,000 shares of the company's common stock on June 22, 2026. The transaction, valued at approximately $10.6 million, was conducted through a Rule 10b5-1 trading plan established earlier in the year. The sale occurred as APGE's stock traded ne…
Janice Suzann Drew, Chief of Development Operations at Evommune, Inc. (NASDAQ:EVMN), executed a significant sale of company stock on June 22, 2026. The transaction, valued at $452,600, followed the exercise of employee stock options earlier the same day. This activity occurs against a backdrop of positive clinical trial developments and financial r…
Christian Kleinerman, Executive Vice President of Product Management at Snowflake Inc. (NASDAQ: SNOW), has executed a series of stock transactions involving the company’s common stock, as disclosed in recent filings. These transactions include both sales under a pre-arranged trading plan and shares withheld for tax obligations. The activity occurs …
Omada Health, Inc. (NASDAQ:OMDA) President Shao Wei-Li executed a share sale under a pre-arranged 10b5-1 trading plan, while the company reported first-quarter 2026 financial results that beat earnings forecasts and saw significant revenue growth. Concurrently, Citizens raised its price target for the stock, and the company completed its 2026 Annua…
Fund 1 Investments, LLC, a significant 10% shareholder in Citi Trends Inc (NASDAQ: CTRN), executed a substantial divestiture of its holdings in the apparel retailer. The transaction involved the sale of 750,000 shares on June 24, 2026, totaling approximately $42.37 million. This reduction in ownership occurs against a backdrop of strong recent perf…
Yvonne Wassenaar, a member of the board of directors at Rubrik, Inc. (NASDAQ: RBRK), recently completed the sale of 676 shares of the company's Class A Common Stock. The transaction, valued at $50,700, was executed on June 23, 2026, at a price of $75.00 per share. This disposition was carried out in accordance with a Rule 10b5-1 trading plan that W…
Investment vehicles managed by OrbiMed Advisors LLC have executed a substantial divestment in Enliven Therapeutics, Inc. (NASDAQ: ELVN), selling approximately $39 million worth of common stock. The transaction, recorded on June 22, 2026, involved the disposal of 860,123 shares at prices between $45.00 and $45.38. This sale occurs as Enliven's stock…
CoreWeave, Inc. (CRWV) Chief Development Officer Brannin McBee executed a series of stock sales on June 22, 2026, moving 28,000 shares of Class A Common Stock through two distinct irrevocable trusts. The transactions, valued at approximately $3.1 million, were conducted under a Rule 10b5-1 trading plan established in March 2026. This activity occur…
Daniel D. Long, Septerna’s Senior Vice President of Drug Discovery, executed a series of structured equity transactions on June 22, 2026, selling $532,581 in company stock under a Rule 10b5-1 plan. The sale occurred while the stock traded near $36.05, close to its 52-week high of $37.99, following a 237% annual gain. The transactions were part of a…
CoreWeave, Inc. (NASDAQ: CRWV) reports executive stock divestment under a Rule 10b5-1 framework, coinciding with a broader corporate strategy focused on AI infrastructure expansion and capital raising. The transaction details, shareholding structure, and recent corporate developments provide a snapshot of the company's operational and financial pos…
Brannin McBee, serving as Chief Development Officer at CoreWeave, Inc. (NASDAQ: CRWV), executed a series of transactions resulting in the sale of approximately $5.84 million in Class A Common Stock on June 22, 2026. The divestment involved 52,500 shares traded at prices between $106.63 and $119.00 per share, conducted through a Rule 10b5-1 trading …
Jason A. Leverone, Chief Financial Officer of OnKure Therapeutics, Inc. (NASDAQ:OKUR), completed a sale of 303 shares of Class A Common Stock on June 22, 2026. The transaction, valued at $1,332, was an automatic sale to satisfy tax withholding requirements associated with restricted stock units vesting under the company's 2023 RSU Equity Incentive …
Markel Stacy, Nuvation Bio Inc.'s Chief People Officer, executed a $753,187 sale of 125,000 Class A Common Stock shares on June 23, 2026, under a pre-arranged 10b5-1 plan. This transaction occurs as Nuvation Bio reports robust Q1 2026 financials, surpassing revenue forecasts, and announces a significant manufacturing partnership with Thermo Fisher …
Dirk Kersten, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), executed a series of stock sales totaling approximately $5.46 million in late June 2026. The transactions were conducted under a Rule 10b5-1 trading plan adopted by ForDyne B.V. in November 2025. The sales occurred as the company's stock traded near $20.35, following a significant 91…
ICONIQ Strategic Partners, a significant shareholder in ServiceTitan (TTAN), has executed a series of sales totaling approximately $6.00 million in Class A Common Stock over two trading days in late June. This transaction occurs as the stock trades near $65.03, reflecting a substantial 40% decline over the preceding six months. Despite the recent d…
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), executed a sale of 63,000 Class A Common Stock shares on June 23, 2026, realizing approximately $379,190 through a pre-established 10b5-1 plan. This transaction follows the exercise of stock options at $2.93 per share and occurs against a backdrop of robust first-quarter …
Jarrod M Patten, a director at Strategy Inc (NASDAQ:MSTR), recently completed a transaction involving the sale of 1,500 shares of the company's Class A Common Stock. The sale, executed on June 23, 2026, was part of a structured process that included the prior exercise of stock options. This activity occurs against a backdrop of significant corporat…
Philippe Sauvage, Chief Financial Officer of Nuvation Bio Inc. (NASDAQ:NUVB), has executed a sale of 47,668 shares of the company's Class A Common Stock, totaling $286,370. This transaction, carried out on June 23, 2026, was conducted under a pre-arranged 10b5-1 trading plan established in December 2025. The sale follows a significant price appreci…
Box Inc. (NASDAQ:BOX) Chief Executive Officer Aaron Levie divested 15,000 shares of Class A Common Stock on June 22, 2026, generating $364,830 at a weighted average price of $24.322 per share. The transaction, governed by a Rule 10b5-1 plan initiated on March 20, 2026, reduces Levie’s direct holdings to 2,874,673 shares, including restricted stock …
